Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS -- Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Blast caused mTBI is considered to be the signature injury effecting soldiers where brain injury from explosive devices and artillery fire blast exposure is highly prevalent. Read More